Home » Stocks » MEDS

Trxade Group, Inc. (MEDS)

Stock Price: $5.87 USD -0.11 (-1.84%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $5.95 +0.08 (1.36%) Jan 15, 7:46 PM
Market Cap 47.51M
Revenue (ttm) 16.82M
Net Income (ttm) -719,096
Shares Out 8.06M
EPS (ttm) -0.14
PE Ratio n/a
Forward PE 17.64
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $5.87
Previous Close $5.98
Change ($) -0.11
Change (%) -1.84%
Day's Open 6.00
Day's Range 5.70 - 6.09
Day's Volume 116,644
52-Week Range 4.10 - 7.96

News

Hide News
GlobeNewsWire - 1 month ago

TAMPA, FL, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Trxade Group, Inc. ( MEDS ) an integrated drug procurement, delivery and healthcare platform, today announced that management will present at the D...

24/7 Wall Street - 2 months ago

Trxade Group Inc. (NASDAQ: MEDS) shares jumped on Tuesday after the company announced that it entered into a definitive agreement with Amazon.com Inc.

Other stocks mentioned: AMZN
Market Watch - 2 months ago

Shares of Trxade Group Inc. soared 56% in active trading to pace all of the premarket's gainers Tuesday, after the online platform for pharmaceutical purchases announced a market program agree...

About MEDS

Trxade Group, together with its subsidiaries, owns and operates a business-to-business (B2B) web-based marketplace focused on the pharmaceutical industry in the United States. It operates through Trxade, Inc.; Community Specialty Pharmacy, LLC; Integra Pharma, LLC; and Other segments. The company operates a web based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services. Its principal products and services include Trxade.com, a web-based pharmaceutical marketplace; InventoryRx.co... [Read more...]

Industry
Pharmaceutical Retailers
IPO Date
Feb 13, 2020
CEO
Surendra K. Ajjarapu
Employees
29
Stock Exchange
NASDAQ
Ticker Symbol
MEDS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Trxade Group stock is "Buy." The 12-month stock price forecast is 12.17, which is an increase of 107.33% from the latest price.

Price Target
$12.17
(107.33% upside)
Analyst Consensus: Buy